Back to Journals » Vascular Health and Risk Management » Volume 6

Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice

Authors Bramlage P, Wolf W, Stuhr T, Fronk E, Erdlenbruch W, Ketelhut R, Schmieder RE

Published 27 August 2010 Volume 2010:6 Pages 803—811

DOI https://doi.org/10.2147/VHRM.S13441

Review by Single-blind

Peer reviewer comments 3


Peter Bramlage1, Wolf-Peter Wolf2, Thomas Stuhr2, Eva-Maria Fronk3, Wolfhard Erdlenbruch2, Reinhard Ketelhut4, Roland E Schmieder5
1Institute for Cardiovascular Pharmacology and Epidemiology, Mahlow; 2Daiichi Sankyo Deutschland GmbH, Munich, Germany; 3Daiichi Sankyo Europe GmbH, Munich, Germany; 4Department of Sports Medicine, Universitätsklinikum Berlin; 5Department of Nephrology and Hypertension, University Hospital of Erlangen, Germany
Objectives: To assess the efficacy and tolerability of a fixed-dose combination of olmesartan and amlodipine in an unselected population of patients in primary care and to compare the results with recent randomized controlled trial evidence.
Methods: A multicenter, noninterventional, noncontrolled observational study with 8241 hypertensive patients seen by 2187 physicians in daily practice. Blood pressure (BP) reduction, comorbid disease, pharmacotherapy, and tolerability were documented over a 12–18-week observational period.
Results: Patients had a mean age of 62.8 ± 11.8 years (48.1% female), and 74.8% had at least one comorbid risk factor or condition. In total, 51.3% received olmesartan-amlodipine 20/5 mg, 30.6% received 40/5 mg, and 17.9% received 40/10 mg at baseline, mostly because of lack of efficacy on prior antihypertensive therapy (73.8%). BP at baseline was 161.8 ± 16.6/93.6 ± 10.2 mmHg (39.8% had Grade 2 hypertension), and the observed BP reduction was -29.0 ± 17.1/-13.5 ± 10.9 mmHg (P < 0.0001), with a significant correlation between BP at baseline and BP reduction (Spearman’s Rho -0.811 for systolic BP and -0.759 for diastolic BP). BP reduction appeared to be dependent on dose and prior antihypertensive therapy, but not on age, gender, body mass index, duration of hypertension, or the presence of diabetes. At the final visit, 69.4% (4.3% at baseline) were controlled (<140/90 mmHg). Adverse drug reactions were observed in 2.76% of the study population; 94.25% of these adverse drug reactions were judged as nonserious events, and 31.5% of all adverse drug reactions reported were peripheral edema.
Conclusion: The fixed-dose olmesartan-amlodipine combination was effective and well tolerated in an unselected population of patients in primary care practice. These results confirm prior randomized controlled trial evidence.
Keywords: blood pressure, cardiovascular risk, antihypertensive treatment, observation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]